Hycamtin 4 Mg Powder For Concentrate For Solution For Infusion (Topotecan)

Topotecan powder for infusion is indicated for the treatment of several malignant neoplasms where DNA replication inhibition is desired.

• Ovarian cancer, especially in patients with recurrent disease.
• Small cell lung cancer, typically in combination with other cytotoxic agents.
• Cervical cancer, for advanced or metastatic disease.
• Occasionally used off‑label for other solid tumors under specialist supervision.

• Topotecan exerts its antineoplastic activity by binding to the DNA‑topoisomerase I enzyme‑DNA complex. This stabilizes the transient single‑strand breaks introduced by topoisomerase I during DNA unwinding, preventing relegation of the DNA strands. The resulting accumulation of DNA breaks interferes with DNA replication and transcription, and impairs repair mechanisms, ultimately triggering cell‑cycle arrest and apoptotic cell death in rapidly dividing tumor cells.

Adverse reactions to topotecan infusion vary in frequency and severity.

Common

• Nausea and vomiting, often requiring antiemetic support.
• Diarrhea or constipation, which may need symptomatic management.
• Decreased white blood cell count (neutropenia), increasing infection susceptibility.

Serious

• Severe neutropenia with febrile infection, potentially requiring hospitalization.
• Thrombocytopenia leading to bleeding or bruising, necessitating platelet monitoring.
• Acute allergic reactions, including anaphylaxis, that demand immediate medical intervention.

Before initiating topotecan infusion, clinicians should evaluate several safety considerations to reduce the risk of complications.

• Assess baseline blood counts and organ function (renal, hepatic).
• Monitor for signs of infection due to neutropenia.
• Adjust dose in patients with impaired renal function.
• Use caution in patients with pre‑existing cardiac disease.
• Avoid use during pregnancy unless benefits outweigh risks.
• Counsel patients on potential hair loss and gastrointestinal symptoms.

Topotecan may interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use of strong CYP3A4 inducers (e.g., rifampin) that may lower exposure.
• Co‑administration with other myelosuppressive agents without dose adjustment.

Use with caution

• Antiemetics that prolong QT interval (e.g., ondansetron) may increase cardiac risk.
• Drugs that affect renal clearance (e.g., high‑dose NSAIDs).
• Vaccines containing live attenuated viruses while immunosuppressed.